Media headlines about Applied Genetic Technologies (NASDAQ:AGTC) have been trending somewhat positive this week, according to Accern. Accern rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Applied Genetic Technologies earned a news impact score of 0.15 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 47.6554622343204 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Applied Genetic Technologies (AGTC) traded down $0.02 on Friday, hitting $3.83. 125,562 shares of the company traded hands, compared to its average volume of 70,186. Applied Genetic Technologies has a 1 year low of $3.25 and a 1 year high of $10.15.
Applied Genetic Technologies (NASDAQ:AGTC) last posted its earnings results on Wednesday, September 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.40). The firm had revenue of $8.30 million during the quarter, compared to analyst estimates of $12.39 million. Applied Genetic Technologies had a negative net margin of 8.78% and a negative return on equity of 2.86%. The business’s revenue for the quarter was down 31.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.15 earnings per share. research analysts anticipate that Applied Genetic Technologies will post -1.14 earnings per share for the current year.
Several equities analysts recently issued reports on AGTC shares. Stifel Nicolaus decreased their target price on shares of Applied Genetic Technologies from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, September 14th. BMO Capital Markets reiterated an “outperform” rating and issued a $7.00 target price (down from $14.00) on shares of Applied Genetic Technologies in a research note on Thursday, September 14th. Cantor Fitzgerald decreased their target price on shares of Applied Genetic Technologies from $15.00 to $9.00 and set a “neutral” rating for the company in a research note on Thursday, September 14th. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price (down from $16.00) on shares of Applied Genetic Technologies in a research note on Thursday, September 14th. Finally, ValuEngine cut shares of Applied Genetic Technologies from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $10.17.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Applied Genetic Technologies (AGTC) Stock Price” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://ledgergazette.com/2017/12/10/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-applied-genetic-technologies-agtc-stock-price.html.
About Applied Genetic Technologies
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).
Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.